Navigation Links
Tasker Products Receives USDA Consent to Begin Immediate Commercialization of Tasker Clear Throughout Entire Poultry Processing Operations
Date:4/15/2008

Tasker's Clear product will be marketed from the Scalder to the Post-Chill

Dip and Spray

FAIR LAWN, N.J., April 15 /PRNewswire-FirstCall/ -- Tasker Products Corp. (OTC Bulletin Board: TKER), a distributor and marketer of proprietary technology effective in inhibiting pathogenic bacteria, today announced that it has received a "Letter of No Objections" from the Food Safety and Inspection Service ("FSIS") of the United States Food and Drug Administration ("USDA") to market its patented Tasker Clear in all sections of poultry processing.

Currently, poultry processors use various acidifiers to control the pH levels of poultry intervention systems. These acidifiers predominately come in dry, powder form that can be corrosive and cumbersome to use in a plant environment and are more expensive and less friendly than liquid solutions. Tasker Clear is an effective acidifier in liquid form, making it easier and less expensive to administer under complex processing conditions.

Commenting on the latest progress, Lanny Dacus, Tasker's president and CEO, said, "This is a major achievement for Tasker. With the poultry processing relationships we have established over the last 18 months, we now have a new product to market that can be immediately deployed and is in wide demand. Our new Tasker Clear product is the only acidifier available in aqueous form. It is highly concentrated, effective and cost competitive. We are excited to receive such a complete response from the USDA. The regulatory consent of this product extends our marketing effort in the poultry industry to include approximately 50 turkey plants, and possibly red meat plants. The quick response received from the USDA on Tasker Clear may accelerate the review, and possible approval, of Tasker's application for red meat."

Tasker Products also has poultry processing applications for its Tasker Blue product. Tasker Blue uses acidified copper sulfate in a pate
'/>"/>

SOURCE Tasker Products Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Tasker Products Rolls Out Scalder Application at Two New Poultry Processors Facilities
2. Healthy Diabetic Bakery Products Launched Nationally
3. Gardasil, Other New Products Spur Strong Vaccine Sales in 2007
4. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
5. Zimmer Announces Actions Affecting its Ohio-based Orthopaedic Surgical Products Operation
6. Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Companys 10-Year Anniversary
7. Natural Elements Reveals Exotic Natural Hawaiian Skin Care Products for Sale on Their Website
8. London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products
9. Schiff(R) Introduces New Supplement Products for Intestinal Health and Beauty Maintenance
10. Sergeants(R) Pet Care Products Acquires the Consumer Brand Division of Virbac Corporation
11. House Health Subcommittee Acts to Protect Kids and Save Lives by Approving Bill to Regulate Tobacco Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...ed for May 19 at 10:15 a.m. Eastern Time, VANCOUV...dical,Corporation (TSX: RBM, OTCBB: RPBIF) today a...r, is scheduled to present at the Rodman & Renshaw... May 19th at 10:15 a.m.,EDT., A live web cast of ...s,Web site at, http://www.responsebio.com/newsroom...
(Date:5/16/2008).../PRNewswire-USNewswire/ -- Emergency Medical,Servi...ght the dedication,of Pennsylvania,s first respond...EMS volunteers, according to state Secretary of He...: Your Life is Our Mission," emphasizes that no,ma...is there to provide,immediate, life-saving care an...
(Date:5/16/2008)...th Drops More in 2007, WASHINGTON, May 16 /PRNews...n three cancer deaths, the National Cancer Institu... budget in lung cancer research in 2007,according...nce (LCA) today., The two other federal agencies ...rs for Disease Control and Prevention (CDC) and th...
(Date:5/16/2008)... disseminated to community physicians, audit finds...Partnerships between major academic cancer centers... way to spread cancer treatment advances, say rese.... , Most new cancer treatments are created at m...ided at community hospitals, noted the researchers...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:Partnerships Effective Communicators of Cancer Advances 2
...rs in New Zealand have warned against using tradit...ed lead poisoning using them, it was reported Frid... substantial threat to well-being posed by a parti...urvedic medicine," doctors said in a report in the...
...hinese soybean lines that grow without the primary...dults have been isolated by scientists//. The two ...ons and will be given away to breeders seeking to ...lergy-free soybeans without genetic engineering. ...
...mittee of MPs have termed the shake-up of the out ...ic" that only led to longer waits and higher costs...e new health care providers are spending 22% more ...ny key targets. In 2004 most GPs had opted out of...
...ar-old girl, Stephanie Mullen, a type 1 diabetic h...that the girl could have probably run out of medic...led for public attention in this matter. Stephani...nday. Stephanie went missing after spending Monday...
Other Medicine News:Health News:Promise for Soya Allergy Sufferers 2
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...tate, Colorectal and Ovarian ...ent on Sun., June 1 with Oncology Experts -, SOUT...all/ -- Poniard,Pharmaceuticals, Inc. (Nasdaq: PA...ogy, today announced that the Company will present... various tumor types and combinations, at,poster s...
(Date:5/15/2008)...cts depth and breadth of, collaboration with inve... diverse forms of cancer -... the leading IV, bisphosphonate, on relapse rate o... oral sessions to feature RAD001, first oral once-...st results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...tCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYSE: ...rk ATHENA study showed Multaq(R) (dronedarone), a ...th atrial fibrillation or atrial flutter,decrease...eath from any,cause by a statistically significant...point. The ATHENA results will be presented at the...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Coalition America Renews Relationship with Musketeer to Offer Streamlined Claims Repricing and Adjudication Solution for Benefit Administrators 1971 1Coalition America Renews Relationship with Musketeer to Offer Streamlined Claims Repricing and Adjudication Solution for Benefit Administrators 1971 2Race Against Pain Coming to California 1968 1Race Against Pain Coming to California 1968 2Race Against Pain Coming to California 1968 3Portico Systems Wins Three Awards in 30 Days 1965 1Portico Systems Wins Three Awards in 30 Days 1965 2Signalife Receives Another 243 3 Million Sales Orders 813 1Signalife Receives Another 243 3 Million Sales Orders 813 2
...nd VANCOUVER, April 26, 2007,/PRNewswire-FirstCall...cialty pharmaceutical and medical device company, ... pivotal trial examining the,Vascular Wrap(TM) Pac... presented today at a scientific forum in Europe. ...y of the Vascular,Wrap(TM) for use in arterial byp...
...pril 26, 2007 /PRNewswire-FirstCall/ --,Australian...nnounced preliminary results from its randomised P... colorectal cancer, where,Alchemia,s drug HyCAMP(T...to be a cornerstone drug for the treatment of colo...a preliminary stage of,the analysis in accordance ...
Other Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7
Toothed Pituitary Rongeurs, 12 300 mm.
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed to give rigid skeletal fixation, which allows surgeons more freedom in positioning fixation pins. It provides 3-point rigid skeletal fixation for the supine, prone, lateral, or sitting
Medicine Products: